The prognosis of patients with myocardial infarction (MI) 
Introduction

Cardiovascular disease (CVD), especially myocardial infarction (MI) with resultant congestive heart failure (CHF), is a leading cause of mortality and morbidity worldwide
. Despite recent improvements in disease prevention and combinative therapy (medical, interventional, device and transplantation) for MI and CHF, the 1 year mortality rate for patients with acute MI and impaired left ventricular function is still only 13% [2] . Furthermore, CHF is associated with a 20% mortality rate per year [3] . The [5, 6] . [7, 8] . [4, 11] and in vivo [5, 12] [74] [75] [76] [77] . Thus, further detailed studies are required to provide exact molecular pathways leading to this protection. [88] . However, the pathways and the putative molecules involved in this mechanism are far from complete, and more studies are required to precisely ascertain this mechanism. [89] . Transplantation of MSCs can significantly improve these adverse changes in infarcted hearts [85] . This study documented that MSC transplantation into the border zone of infarcted hearts caused significant improvement in myocardial contractile performance and reduction in wall stress, ultimately contributing to significant bioenergetic improvement from paracrine repair mechanisms. However, Gnecchi et 
In the last decade scientists have observed that MSCs maintain their multilineaged capacity after expansion and transplantation, and seem to have unique immunological characteristics that allow persistence in a xenogeneic environment. This makes them a promising source for cell therapy in the setting of MI with subsequent CHF. We have observed that administration of MSCs by intravenous, intraventricular or intramyocardial injection can improve myocardial function before and after cardiopulmonary resuscitation (CPR) and duration of survival after CPR in MI rats
Recent studies in clinical experiences have revealed that MSC therapy is safe and may improve cardiac function and structural remodelling in patients with acute MI or CHF [9]. However, the mechanism of beneficial effects from MSC-based therapy for MI is yet to be understood. Multiple biological mechanisms, such as cardiac regeneration, neovascularization, paracrine effect and immunoregulation, and others, may contribute to the efficacy of MSC therapy in acute MI and after MI (Fig. 1). This review focuses on experimental studies and clinical trials with MSCs derived from bone marrow unless specially declared herein, and provides an overview of current knowledge of the underlying mechanisms contributing to their efficacy in therapy for MI.
Transdifferentiation MSCs differentiate into CMCs
MI leads to a significant loss of cells and formation of scar tissue. The remaining CMCs are unable to reconstitute the necrotic tissue, and cardiac function deteriorates during the ensuing course. Orlic
Fig. 1 Proposed repair mechanisms of bone marrow MSCs in MI. Transdifferentiation of MSCs into CMCs and vascular cells leads to cardiac regeneration and vasculogenesis. MSCs can exert actions on different cell types, leading to endogenous cardiac regeneration, neovascularization, anti-inflammation, anti-apoptosis, anti-remodelling, cardiac contractility and cardiac metabolic modulation in a paracrine
Anti-apoptotic effects by MSCs
Accumulating evidence suggests that improved cardiac function is partly associated with inhibition of apoptosis provided by cytokines released from stem cells following transplantation. Transplantation of hypoxic cultured MSCs further enhances morphological and functional benefits in infarcted hearts, in part due to increases of Bcl-2 and its receptor Bcl-xL, which has been shown to prevent cell death and apoptosis under hypoxic conditions [68, 69]. Akt may significantly enhance retention of MSCs engraftment within infarcted myocardium and alter the secretion of various cytokines and growth factors [41]. This study further confirms that early paracrine mechanisms mediated by MSCs are responsible for enhancing the survival of existing myocytes. Conditioned medium from hypoxic Akt-modified MSCs (AktMSCs) markedly inhibits hypoxia-induced apoptosis and triggers vigorous spontaneous contraction of adult rat CMCs in vitro, and significantly limits infarct size and improves cardiac performance in comparison with controls in vivo [42]. These protective effects are postulated to be associated with levels of growth factors, such as VEGF, FGF-2, HGF, IGF-I and thymosin ␤4 (TB4). It has also been shown that Akt-MSCs promote CMC survival through paracrine mechanisms mediated by Sfrp2 via increasing cellular ␤-catenin and up-regulating expression of anti-apoptotic genes Birc1b and Bcl2, and others in vivo and in vitro [70]. Wang et al. have revealed that conditioned medium from MSCs engineered with heat-shock protein-20 protected adult rat CMCs against oxidative stress, possibly via enhanced activation of Akt and increased secretion of growth factors VEGF, FGF-2 and IGF-1 [71]. It has been indicated that MSC transplantation may have significant beneficial effects on injured heart function independent of cardiac regeneration and SDF-1 secreted by MSCs may play a role in trophic support for cardiac myocytes after MI [72]. The indirect evidence also comes from that pre-treatment of MSCs with a combination of FGF-2, IGF-1 and BMP-2, reduced apoptosis of neighbouring CMCs in a hypoxic condition and enhanced the phosphorylated Akt and phosphorylated cyclic adenosine monophosphate (cAMP) response element binding protein expression of CMCs, resulting in smaller infarct size and better cardiac function [73]. The pathways by which MSCs exert the property of anti-apoptosis are far from clear, possibly that cardiac regulation of Bcl-2/Bax ratio and activation of PI3K/Akt, mitogen-activated protein kinases pathways, including extracellular signal-regulated kinase (ERK), c-JUN N-terminal kinase (JNK) and p38, and activation of caspase-3 may be involved in this paracrine effect
Cardiac remodelling induced by paracrine effects
The remodelling of the left ventricle following MI represents a major cause of infarct-related heart failure and death. The majority of experiments have revealed that transplantation of MSCs can influence extracellular matrix remodelling through regulation of MMPs and matrix metalloproteinase endogenous inhibitor (TIMP) production and enhancing expression of anti-fibrotic factors, contributing to attenuation in cardiac remodelling after MI. MSCs may also exert paracrine anti-fibrotic effects to attenuate ventricular remodelling through regulation of cardiac fibroblasts (CFB) proliferation. It has been revealed that MSC-conditioned medium up-regulates anti-proliferation-related genes such as elastin
Cardiac metabolic modulation by MSCs
Abnormalities in myocardial energy metabolism may contribute to contractile dysfunction and the progressive worsening of ventricular function following MI. MSCs are characterized by metabolic flexibility and postulated to possess the potential to positively affect myocardial metabolism after administration into the MI heart. Hu and colleagues found that profound bioenergetic abnormalities characterized by decrease in ATP levels, phosphocreatine-to-ATP ratio and mitochondrial F(1)F(0)-ATPase in peri-infarcted myocardial regions may contribute to the transition from compensated left ventricular remodelling to CHF following MI
